Ultra-Hypofractionated RT May Offer Convenience in Elderly Breast Cancer
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Forming Connections and Making a Difference in the Brain Cancer Field
The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.
Ultra-Hypofractionated Radiation May Mitigate Breast Cancer Recurrence
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
Elacestrant Combo Shows Activity, Tolerability in Metastatic Breast Cancer
Investigators report no grade 4 adverse effects among patients who received elacestrant/abemaciclib in the phase 1b/2 ELECTRA trial.
Exploring the Use of Ultra-Hypofractionated RT in Elderly Breast Cancer
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Novel BCL-2 Inhibitor Combo Shows Enduring Responses in R/R Myeloma Subtype
Data from a phase 1b/2 trial show that sonrotoclax/dexamethasone appears to be well tolerated in a heavily pretreated multiple myeloma population.
Quadruplet Therapy Shows Benefit for Newly Diagnosed Multiple Myeloma
Thomas G. Martin, MD, discussed the advantages of quadruplet therapy for multiple myeloma in light of an FDA approval for Isa-VRd in this indication.
Nivolumab/RT Improves Biochemical Recurrence Outcomes in Prostate Cancer
Phase 2 data support further evaluation of nivolumab plus standard radiotherapy in patients with Gleason grade 5 prostate cancer.
FDA Approves Noninvasive Stool DNA Test for Colorectal Cancer Screening
Data from the BLUE-C trial support the approval of the Cologuard Plus test for colorectal cancer screening among at-risk individuals.
Isatuximab Combo Yields MRD-Negative Responses in Transplant-Eligible NDMM
Nearly all patients in the per-protocol population of the MIDAS study achieved a very good partial response or better following study treatment.
Daratumumab Combo Yields MRD-Negative Status in Transplant-Ineligible NDMM
Phase 3 data support a daratumumab-based quadruplet as a new potential regimen in transplant-ineligible newly diagnosed multiple myeloma.
Neoadjuvant Sotigalimab Proves Efficacious in Rectal Cancer
Results from the INNATE trial showed the use of sotigalimab to be a safe and efficacious regimen for patients with rectal cancer.
Concurrent Chemoradiation/Atezolizumab Does Not Improve Survival in LS-SCLC
Data show that twice-daily radiotherapy may confer improved survival vs once-daily radiation in patients with limited-stage small cell lung cancer.
Acalabrutinib Earns FDA Priority Review in Untreated Mantle Cell Lymphoma
The FDA has set a Prescription Drug User Fee Act date in the first quarter of 2025 for the potential approval of acalabrutinib in previously untreated MCL.
Neoadjuvant/Adjuvant Nivolumab/Chemo Approved by FDA in Resectable NSCLC
Findings from the phase 3 CheckMate 77T trial support the approval of nivolumab plus chemotherapy for resectable NSCLC.
Adjuvant cCRT Improves Disease Control, But Increases AEs in Breast Cancer
Concurrent chemoradiation yielded similar contralateral breast recurrence outcomes vs a sequential approach in early-stage breast cancer.
Adding Bortezomib to Isa-Rd Elicits Durable Responses for Multiple Myeloma
Adding bortezomib to Isa-Rd triplet therapy enhanced MRD-negative responses in patients with transplant-ineligible multiple myeloma.
Isatuximab Quadruplet Therapy Appears Well Tolerated in Multiple Myeloma
Isatuximab plus VRd triplet therapy did not significantly increase toxicity in patients with transplant-ineligible multiple myeloma in the IMROZ trial.
Isatuximab Quadruplet Therapy Shows PFS Advantage in Multiple Myeloma
Isatuximab quadruplet therapy for patients with multiple myeloma prolonged progression-free survival when compared with VRd triplet therapy.
Biosignature Test May Predict Residual Risk Post-BCS/RT in HER2+ DCIS
Use of DCISionRT may open new options for tailored treatments among patients with HER2-positive ductal carcinoma in situ.
Retrospective Radiotherapy in IBD Data May Warrant Prospective Research
Retrospective study data show that patients with inflammatory bowel disease may not require modification of standard radiotherapy for pelvic malignancies.
Retrospective Study Provides Initial Toxicity Data in Radiation-Treated IBD
Prospective trial data may help guide treatment planning for patients with inflammatory bowel disease planning to undergo radiotherapy.
HDP-101 Demonstrates Preliminary Efficacy in R/R Multiple Myeloma
Investigators anticipate launching the dose-expansion portion of the phase 1 HDP-101-01 trial in 2025.
177Lu-Dotatate Improves PFS in Recurrent Meningioma
Efficacy findings were enhanced when 177Lu-Dotatate was used to treat patients with grade II/III recurrent meningioma.
Adaptive Radiotherapy Modality Appears Safe, Feasible in High-Grade Glioma
UNITED is the first trial to assess MR-guided weekly adaptive on-line and real-time radiotherapy with clinical target volume margin reductions.
Support Groups May Help Manage Talquetamab-Related AEs in Multiple Myeloma
Samantha Shenoy, NP, MSN, suggests that support groups may help comfort patients experiencing adverse effects negatively impacting quality of life.
T-DXd Earns FDA Priority Review in Pretreated HER2-Low Breast Cancer
Data from DESTINY-Breast06 support the priority review designation for T-DXd as a treatment for HER2-low or HER2-ultralow breast cancer.
Starting at the Front Line in Metastatic Pancreatic Cancer As New Options Emerge, How Do You Select and Sequence?
Experts in gastrointestinal cancer focus on frontline therapy options for patients with pancreatic cancer.
Assessing NP Roles in Talquetamab Treatment for Multiple Myeloma
A nurse practitioner discussed how her role plays a vital part in patient care for those undergoing talquetamab treatment for multiple myeloma.
Novel PET Imaging Agent Earns Fast Track Status for PSMA+ Prostate Cancer
In 2 clinical trials, 64Cu-SAR-bisPSMA was shown to be effective in detecting prostate cancer in patients with PSMA-positive lesions.
